 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12345678910111213...1920» |
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Enrollment closed: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Oct 3, 2023
P3, N=724, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Journal: Survival and Local Recurrence Risk in Patients with High-Risk Neuroblastoma Treated with Proton Therapy over a 10 Year Interval. (Pubmed Central) - Oct 3, 2023
A small number of pts received 21.6 Gy after STR, however, this experience suggests that a subset of pts with RD may require RT dose > 21.6 Gy. Further work is required to further characterize individual management of PS in pts with HR-NBL with regard to extent of RD and biologic disease features.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Survival and Local Recurrence Risk in Patients with High-Risk Neuroblastoma Treated with Proton Therapy over a 10 Year Interval (Hall B2; In Person Only; Screen: 7) - Oct 2, 2023 - Abstract #ASTRO2023ASTRO_2590;
Our data suggest that LR is rare after GTR and 21.6 Gy, and uncommon among pts with STR treated with 36 Gy. A small number of pts received 21.6 Gy after STR, however, this experience suggests that a subset of pts with RD may require RT dose > 21.6 Gy.
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Trial primary completion date, Combination therapy: ANBL19P1: Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Oct 2, 2023
P2, N=34, Active, not recruiting, Sponsor: Children's Oncology Group
A small number of pts received 21.6 Gy after STR, however, this experience suggests that a subset of pts with RD may require RT dose > 21.6 Gy. Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Jun 2023
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open: Rapid Administration Pilot for Infusing Dinutuximab (clinicaltrials.gov) - Sep 28, 2023
P4, N=11, Recruiting, Sponsor: Children's Hospital Los Angeles
Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Jun 2023 Not yet recruiting --> Recruiting
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Journal: Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction. (Pubmed Central) - Sep 28, 2023
The EOI response of PR or better in the evaluable cohort was 96%. Dinutuximab was well tolerated with all Induction cycles, demonstrated an encouraging EOI response rate, and should be evaluated in a randomized study.
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Journal: Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer. (Pubmed Central) - Sep 25, 2023
The combination of a SLC7A5 blockade mediated via JPH203 treatment and an anti-programmed cell death 1 (PD-1) antibody synergistically increased the immune cell infiltration rate and inhibited tumor progression. Hence, our results highlight the molecular mechanisms underlying SLC7A5 effects and lead to a better understanding of the potential benefit of targeting glutamine metabolism in combination with immunotherapy as a new therapy for TNBC.
- | OP-11 / Ohara Pharma
Journal: Design and Synthesis of 1,3,5-Triazines or Pyrimidines Containing Dithiocarbamate Moiety as PI3K? Selective Inhibitors. (Pubmed Central) - Sep 22, 2023
inhibitors that have not been reported in the literature...In addition, compound 13 induced obvious tumor regression in the U87-MG cell line xenografts mouse model, with no obvious signs of toxicity after intraperitoneal injection at a dose of 40 mg/kg. Compound 13 can be an effective selective inhibitor of PI3K?, and it provides patients with an opportunity to avoid the side effects related to the wider inhibition of the class I PI3K family.
- nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Contribution of Amino Acid Transporter SLC7A5 to Pathological Ventricular Hypertrophy and Heart Failure (Zone 1, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_7025;
LAT1 overexpression occurs in cardiomyocytes and contributes to adverse cardiac remodeling via mTOR pathway activation. We propose LAT1 inhibition as a novel therapeutic strategy against HF.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal: Molecular insights of a CBP/?-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder. (Pubmed Central) - Sep 18, 2023
PRI-724-treated NASH mice not only recovered from NASH-related liver fibrosis through the effect of PRI-724 down-regulating the expression of pro-fibrotic genes and up-regulating the expression of anti-fibrotic genes, but they also recovered from NASH-induced liver disorder. PRI-724, a selective CBP/?-catenin inhibitor, thus shows a potent therapeutic effect for NASH-related liver fibrosis and for decreasing adipose tissue in the liver.
- | OP-11 / Ohara Pharma
Journal: Structure-based drug design, synthesis, and biological evaluation of novel 1,3,5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3K? selective inhibitors. (Pubmed Central) - Sep 18, 2023
Here, we described a series of PI3K? inhibitors with 1,3,5-triazine or pyrimidine skeleton containing benzoyl hydrazine based on the pan-PI3K inhibitor ZSTK474 relying on the strategies of structure-based drug discovery (SBDD) and computer-aided drug design (CADD)...Furthermore, compound F8 induced significant tumor regressions in a xenograft mouse model of U87-MG cell line with no clear evidence of toxicity following intraperitoneal injection of 40
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of dinutuximab ? for the treatment of high-risk neuroblastoma in China. (Pubmed Central) - Sep 16, 2023
Results found that dinutuximab ? is not a cost-effective treatment option for children with high-risk NB unless its price is significantly reduced.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma, magrolimab (ONO-7913) / Ono Pharma
Trial completion date, Trial primary completion date: Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma (clinicaltrials.gov) - Sep 13, 2023
P1, N=82, Suspended, Sponsor: National Cancer Institute (NCI)
is not a cost-effective treatment option for children with high-risk NB unless its price is significantly reduced. Trial completion date: Jan 2024 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Jun 2026
- | Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Journal: PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase. (Pubmed Central) - Sep 12, 2023
The activation energy of denaturation of PEG-crisantaspase (307.1?kJ?mol) was higher than for crisantaspase (218.1?kJ?mol) and Glyco-crisantaspase (120.0?kJ?mol), which means that more energy is required to overcome the energy barrier of the unfolding process. According to our results, PEG-crisantaspase is more thermostable than its native form, while Glyco-crisantaspase is more thermosensitive.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal, IO biomarker: A Deeply Quiescent Subset of CML LSC Depend on FAO Yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I. (Pubmed Central) - Sep 11, 2023
We investigated the biological aspects related to LSC heterogeneity in CML patients and demonstrated the ability of specific small molecule CBP/?-catenin antagonists to safely eliminate deeply quiescent therapy resistant CSC. These observations may represent an attractive generalizable therapeutic strategy that could help develop better protocols to eradicate the quiescent LSC population.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal: ?-catenin inhibitor ICG-001 suppress cell cycle progression and induce autophagy in endometrial cancer cells. (Pubmed Central) - Sep 9, 2023
Autophagy inhibition by ATG5 silencing enhanced ICG-001-mediated suppression of cell viability, tumor spheroid formation, and protein expression of cyclin A and CD44. This study clarified the mechanism and revealed the clinical potential of ICG-001 against endometrial cancer.
- || foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Trial completion, Trial completion date: Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia. (clinicaltrials.gov) - Sep 8, 2023
P1, N=5, Completed, Sponsor: Kiminori Kimura, MD
This study clarified the mechanism and revealed the clinical potential of ICG-001 against endometrial cancer. Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Dec 2022
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Journal: Ultraviolet B radiation-induced JPH203-loaded keratinocyte extracellular vesicles exert etiological interventions for psoriasis therapy. (Pubmed Central) - Sep 7, 2023
In an imiquimod-induced psoriatic model, J@EV significantly ameliorated the related symptoms as well as suppressed the over-activated immune reaction, evidenced by the decreased keratinocyte hyperplasia, Th17 expansion, and IL17 release. This study shows that J@EV exerts therapeutic efficacy for psoriasis by suppressing LAT1-mTOR involved keratinocyte hyperproliferation and Th17 expansion, as well as inhibiting IL-1-NF-?B mediated inflammation, representing a novel and promising strategy for psoriasis therapy.
- | Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
New P1 trial: A Phase 1, Single Centre, Open Label, Single Dose, Pharmacokinetic Study of Erwinaze in Healthy Adult Volunteers (EUDRACT) - Aug 31, 2023
P1, N=12, Not yet recruiting, Sponsor: Porton Biopharma Limited
- An Update on Higher Risk Myelodysplastic Syndromes () - Aug 31, 2023 - Abstract #SOHO2023SOHO_939;
Therapies The current treatment landscape for HR-MDS is limited to HMA monotherapy, either parenteral (azacitidine or decitabine) or a more recently available oral option (decitabine/cedazuridine), followed by allogeneic hematopoietic stem cell transplant when feasible based on patient fitness and donor availability.14,15 There is a great need for alternative agents in the front-line and HMA-failure settings, as outcomes are particularly dismal in the latter.16,17 Unfortunately, drug development in MDS has been hampered by poorly-understood disease biology, lack of quality animal models, broad heterogeneity in disease phenotype, and suboptimal patient accrual to trials.18,19 Therapies more recently approved in AML are now being evaluated in HR-MDS. Liposomal daunorubicin/cytarabine (CPX-351) in the front-line setting has some promising, albeit limited, data published so far.20
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Preclinical, Journal: Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models. (Pubmed Central) - Aug 30, 2023
Our results demonstrated that nanvuranlat (JPH203), a high-affinity LAT1-selective inhibitor, suppressed B16-F10 cell proliferation, migration, and invasion...Our findings revealed that the downregulation of the mTOR signaling pathway, induced by LAT1 inhibitors, decreased the expression of integrin ?v?3, contributing to the suppression of metastasis. These results highlight the critical role of LAT1 in cancer metastasis and suggest that LAT1 inhibition may serve as a potential target for anti-metastasis cancer therapy.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Journal, IO biomarker: The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1. (Pubmed Central) - Aug 13, 2023
Patients with relapsed neuroblastoma are often treated with immunotherapy such as the anti-GD2 antibody, dinutuximab, in combination with chemotherapy...The mechanism of ST8SIA1 suppression by YAP is independent of PRRX1 expression, a mesenchymal master transcription factor, suggesting YAP may be the downstream effector of mesenchymal GD2 resistance. These results therefore identify YAP as a therapeutic target to augment GD2 immunotherapy responses in patients with neuroblastoma.
- ||||| Amnolake (tamibarotene) / Syros
Enrollment change: SELECT MDS-1: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 9, 2023
P3, N=550, Recruiting, Sponsor: Syros Pharmaceuticals
These results therefore identify YAP as a therapeutic target to augment GD2 immunotherapy responses in patients with neuroblastoma. N=190 --> 550
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Intraoperative Molecular Imaging with 111In-Dinutuximab-IR800 in a Rat Model of Neuroblastoma (In Person) - Aug 3, 2023 - Abstract #ACSCLINCON2023ACS_CLINCON_3346;
N=190 --> 550 Abstract is embargoed at this time.
- || SPN-820 / Navitor Pharma, Supernus Pharma, nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Review, Journal: Targeting upregulation of the immunosuppressive activity of MDSCs with indirubin as a novel strategy to alleviate psoriasis. (Pubmed Central) - Aug 2, 2023
Abstract is embargoed at this time. This study demonstrates indirubin's pharmacological and therapeutic effects, providing a basis for future clinical application in treating psoriasis.
- || Vesanoid (tretinoin) / Roche, Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
Review, Journal: The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away. (Pubmed Central) - Jul 29, 2023
through strong SE levels in the gene locus and increased sensitivity to tamibarotene. Combined with a hypomethylating agent, synthetic retinoids have shown synergistic anti-leukemic effects in non-APL AML preclinical models and are now being studied in phase II and III clinical trials.
- | Kidrolase (L-asparaginase) / Jazz, Merck (MSD), Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma, Oncaspar liquid (pegaspargase) / Servier
Journal: Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases. (Pubmed Central) - Jul 29, 2023
Combined with a hypomethylating agent, synthetic retinoids have shown synergistic anti-leukemic effects in non-APL AML preclinical models and are now being studied in phase II and III clinical trials. Monitoring of AEA can help to identify patients with 'silent inactivation' and their asparaginase therapy can thus be optimized.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Preclinical, Journal, IO biomarker: IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. (Pubmed Central) - Jul 26, 2023
Monitoring of AEA can help to identify patients with 'silent inactivation' and their asparaginase therapy can thus be optimized. IgA3.0 ch14.18 is a promising new therapy for neuroblastoma, showing (1) increased half-life compared to natural IgA antibodies, (2) increased protein stability enabling effortless production and purification, (3) potent CD89-mediated tumor killing in vitro by healthy subjects and patients with neuroblastoma and (4) antitumor efficacy in long-term mouse neuroblastoma models.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Ketamine as an Adjunct to Opioid Analgesia in Pediatric Patients with High-risk Neuroblastoma Undergoing Treatment with Dinutuximab (South: Hall F) - Jul 20, 2023 - Abstract #ASA2023ASA_1636;
Daily average of IV morphine milligram equivalents (MME) and ketamine intake was calculated for each cycle of dinutuximab. Preliminary findings suggest an acceptable adverse effect profile with ketamine use as an adjunctive opioid therapy to relieve pain in pediatric patients receiving dinutuximab infusions.
- | Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Journal: Back to the future: the amazing journey of the therapeutic antileukemia enzyme asparaginase Erwinia chrysanthemi. (Pubmed Central) - Jul 20, 2023
An asparaginase product displaying the same characteristics of the Erwinia chrysanthemi asparaginase recently has been produced by use of recombinant technology, thus securing a preparation available for use as an alternative, or as a back-up in case of shortages, for the non-recombinant product. The long journey of the Erwinia chrysanthemi asparaginase product as it has developed throughout the last several decades has made it possible for almost every child and adult with ALL to complete the asparaginase-based protocol treatment when an immunological reaction has occurred to any Escherichia coli asparaginase product.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal: Assessment of the structure-activity relationship and antileukemic activity of diacylpyramide compounds as human ClpP agonists. (Pubmed Central) - Jul 19, 2023
We previously developed ZG111, a potent ClpP agonist derived from ICG-001, inhibits the proliferation of pancreatic ductal adenocarcinoma cell lines in vitro and in vivo by degrading respiratory chain complex proteins...Finally, ZG36 treatment inhibited 3-D cell growth in vitro and suppressed the tumorigenesis of AML cells in xenografted mice models. Collectively, we developed a new class of human ClpP agonists that can be used as potential antileukemic therapies.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma, Erivedge (vismodegib) / Roche
Journal: Combinations of PRI-724 Wnt/?-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells. (Pubmed Central) - Jul 18, 2023
Mixtures of PRI-724 and vismodegib affected cell cycle distribution, greatly reduced cell migration, and downregulated the transcript level of CSC markers, especially POU5F1 encoding OCT4. Combinations of PRI-724 with erlotinib or HS-173 were more potent in inducing apoptosis.
- | Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
Journal: Tamibarotene targets heparin-binding protein for attenuating lung injury in sepsis. (Pubmed Central) - Jul 13, 2023
Combinations of PRI-724 with erlotinib or HS-173 were more potent in inducing apoptosis. These findings demonstrated that tamibarotene lessens sepsis-induced lung injury, and the effect could be exerted by targeting HBP and thereby deregulating the NF-?B signaling pathway.
- nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
EFFECTS OF THE NEWLY DEVELOPED LARGE NEUTRAL AMINO ACID TRANSPORTER1 INHIBITOR, JPH203 ON TUMOR MICROENVIRONMENT IN COLORECTAL CANCER (Science Lounge) - Jul 8, 2023 - Abstract #UEGW2023UEGW_2300;
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Preclinical, Journal: JPH203, a LAT1 inhibitor, alleviates steroid-resistant murine airway inflammation mediated by Th17 cells. (Pubmed Central) - Jun 29, 2023
These findings demonstrated that tamibarotene lessens sepsis-induced lung injury, and the effect could be exerted by targeting HBP and thereby deregulating the NF-?B signaling pathway. No abstract available
- | Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
Journal: Intracellular Drug Delivery Process of Am80-Encapsulated Lipid Nanoparticles Aiming for Alveolar Regeneration. (Pubmed Central) - Jun 28, 2023
Am80-encapsulated SS-OP nanoparticles were taken up into the cells via ApoE, and then Am80 was efficiently delivered into the nucleus via RAR?. These results indicated the usefulness of SS-OP nanoparticles as drug delivery system carriers of Am80 for COPD treatment.
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Journal: The Selective LAT1 Inhibitor JPH203 Enhances Mitochondrial Metabolism and Content in Insulin-Sensitive and Insulin-Resistant C2C12 Myotubes. (Pubmed Central) - Jun 27, 2023
JPH at 2 ?M reduced pAkt signaling and increased extracellular accumulation of isoleucine without inducing changes in BCAA metabolic genes. Collectively, JPH may increase mitochondrial function independent of the mitochondrial biogenic transcription pathway; however, high doses may reduce insulin signaling.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal, Tumor cell: WNT-Conditioned Mechanism of Exit from Postchemotherapy Shock of Differentiated Tumour Cells. (Pubmed Central) - Jun 22, 2023
Collectively, JPH may increase mitochondrial function independent of the mitochondrial biogenic transcription pathway; however, high doses may reduce insulin signaling. these data support the hypothesis that the emergence of differentiated tumour cells from postchemotherapy shock after chemotherapy is due to ectopic activation of WNT signalling pathway genes.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal, Machine learning: Machine learning on large scale perturbation screens for SARS-CoV-2 host factors identifies ?-catenin/CBP inhibitor PRI-724 as a potent antiviral. (Pubmed Central) - Jun 21, 2023
Independent of virus infection, PRI-724 treatment caused cell cycle deregulation which substantiates its potential as a broad spectrum antiviral. Our proposed machine learning concept supports focusing and accelerating the discovery of host dependency factors and identification of potential host-directed antivirals.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal, Stroma: Stromal cell-derived factor-1? regulates chondrogenic differentiation via activation of the Wnt/?-catenin pathway in mesenchymal stem cells. (Pubmed Central) - Jun 21, 2023
These findings provide further evidence for the use of MSCs and SDF-1? in the treatment of cartilage degeneration and osteoarthritis.
- | nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Journal: Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells. (Pubmed Central) - Jun 16, 2023
in the treatment of cartilage degeneration and osteoarthritis. Our study demonstrates the potential of first-in-class LAT1 inhibitor nanvuranlat as a concomitant drug with cytotoxic anticancer drugs, especially gemcitabine, on pancreatic and biliary tract cancers.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Preclinical, Journal, IO biomarker: Medicinal and edible plant Allium macrostemon Bunge for the treatment of testosterone-induced androgenetic alopecia in mice. (Pubmed Central) - Jun 15, 2023
Wnt/?-catenin signaling activation, which induced production of growth factors in hair follicles and, eventually, contributed to the influence of AMB on the hair regrowth. Our findings may contribute to effective utilization of AMB in alopecia treatment.
- ||||| nanvuranlat (JPH203) - J / Pharma, Ohara Pharma
Clinical: 🔥Subgroup analysis of double-blind, placebo-controlled Ph 2 study of the LAT1 inhibitor nanvuranlat in biliary tract cancer 🔎 LAT1 transports neutral amino acids for cancer cell energy 🧐 Interesting concept, but only limited efficacy in BTC @myESMO @OncoAlert @EASLedu… https://t.co/v1Kf91Igxq (Twitter) - Jun 4, 2023
- | abiraterone acetate / Generic mfg.
Journal: Inhibition of Wnt/?-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer. (Pubmed Central) - May 26, 2023
In addition, combined treatment inhibited tumor growth in an in vivo abiraterone-resistant xenograft model, blocked stemness, migration, invasion, and colony formation ability of cancer cells. This study opens new therapeutic opportunity for advanced-stage castration-resistant prostate cancer patients.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal: Downregulated KDM6A mediates gastric carcinogenesis via Wnt/?-catenin signaling pathway mediated epithelial-to-mesenchymal transition. (Pubmed Central) - May 15, 2023
Then, we used ICG001 to block the Wnt/?-catenin signal transduction pathway, and the results revealed that ICG001 could reduce the promoting effect of low KDM6A expression on aggressiveness and EMT in GC cells...The EMT is inhibited by regulating theWnt/?-catenin signaling by KDM6A, which reduces GC cell proliferation, migration, and invasion. KDM6A may be a viable target for GC in clinical therapy.
- foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma, nirogacestat (PF-03084014) / SpringWorks Therap, Daurismo (glasdegib) / Pfizer
THE EFFECT OF CONVENTIONAL CHEMOTHERAPY AFTER EXITING QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA () - May 12, 2023 - Abstract #EHA2023EHA_2569;
Also, HL60 showed a more sensitive pattern to idarrubicin, while OCI-AML3 and KASUMI1 were more sensitive to azacitidine. The results obtained show a greater efficacy of conventional chemotherapy when Hedgehog, Notch and Wnt/?-catenin pathways are inhibited in acute myeloid leukaemia cell lines.Figure.
- Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY () - May 12, 2023 - Abstract #EHA2023EHA_2549;
P2
Notably, SRSF2 was the most common mutation in the ND older unfit AML cohort, consistent withpublished series. While the small number of RARA -positive MDS patients precludes definitive characterization of molecular profiles, data in AML patients suggest that RARA overexpression may be agnostic to known molecular features.
- Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma, Torisel (temsirolimus) / Pfizer
METABOLIC PLASTICITY REVEALS A TARGETABLE VULNERABILITY IN LEUKEMIA (Illusion) - May 12, 2023 - Abstract #EHA2023EHA_2319;
We propose a promising treatment combining an asparagine and glutamine degrader(Erwinase) with a PI3KS inhibitor (Torisel) that should be considered as a therapeutic option in a bridge-to- transplant approach for R/R T-ALL/LL with PI3KS deregulation. We show that metabolic plasticity conveys a unique and targetable vulnerability in PI3KS-driven leukemia that show promising results in pre-clinical and clinical settings.
- | Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
Journal: Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RAR? Agonist, is a Novel Approach in AML. (Pubmed Central) - May 1, 2023
P2
We show that metabolic plasticity conveys a unique and targetable vulnerability in PI3KS-driven leukemia that show promising results in pre-clinical and clinical settings. The combination of oral tamibarotene plus azacitidine was evaluated in a phase 2 clinical study in 51 newly diagnosed unfit patients with AML identified as RARA-positive (n
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance treatment based on a retrospective, blinded independent central review (BICR) of imaging during long-term follow-up. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6665;
P3
The combination of oral tamibarotene plus azacitidine was evaluated in a phase 2 clinical study in 51 newly diagnosed unfit patients with AML identified as RARA-positive (n This BICR indicates minimal, if any, bias in imaging evaluations in the original NMTRC003B study, providing confidence in the finding that DFMO treatment in HNRB patients in remission post upfront dinutuximab approximately halves the risk of relapse compared to matched control patients.